What Symetrel Treats: Main Uses and Benefits

Symetrel is commonly used to help with symptoms of increased neurological or muscular activity related to movement disorders. The medication is used to address symptom clusters that may become intense or disruptive in Parkinson's disease, such as rigidity and slowness. It supports the management of excessive involuntary movements (dyskinesia) that can arise from other Parkinson’s therapies, and is applied in addressing the spasms and tremors of drug-induced extrapyramidal symptoms. This may assist in supporting functional stability and contributes to improved comfort during symptomatic periods.

---

• Quick Fact: Provides supportive relief for Motor Symptoms and Systemic Viral Aches.

Its primary therapeutic relevance includes support for Parkinsonian motor symptoms, easing symptoms of drug-induced extrapyramidal movement disorders, and providing symptomatic assistance during acute Influenza A virus illness. Symetrel is also applied across domains where additional symptomatic support is needed for severe fatigue associated with chronic neurological conditions like Multiple Sclerosis (MS). This use offers symptomatic relief that helps patients cope more steadily by managing the intensity of symptoms related to significant tiredness.

“This medication is relevant across therapeutic areas that involve both motor control difficulties and specific viral symptoms.”

Regulatory References

1. NIH MedlinePlus Drug Information

Official Eligibility Profile for Symetrel

Regulatory authorities define the specific patient populations who can or cannot use Symetrel (Amantadine Hydrochloride). Eligibility is strictly governed by age, specific pre-existing medical conditions, and physiological status.

---

Absolute Contraindications

Symetrel must not be used in patients with a known hypersensitivity to Amantadine or any excipient, or in those with end-stage renal disease (ESRD), which is typically defined as a creatinine clearance below 15 mL/min. The medicine is also formally contraindicated for patients with untreated angle-closure glaucoma.

---

Restricted or Conditional Use

Population Group	Restriction Summary
Renal Impairment	Requires use with caution and a mandatory dose adjustment based on clearance.
Older Adults (65+ years)	Requires caution in dose selection and monitoring due to likely reduced renal function.
Psychiatric Conditions	Requires close monitoring due to potential worsening of psychiatric disorders or psychosis.

---

Age and Reproductive Status

Use is not established in infants under one year of age. Symetrel is contraindicated for women who are pregnant or breastfeeding due to potential risks documented in regulatory labeling.

Symetrel (amantadine) has documented interactions with several categories of medicinal products, primarily impacting the drug's plasma concentration or increasing the risk of certain central nervous system (CNS) side effects.

Affects on Amantadine Clearance

Symetrel is largely excreted unchanged by the kidneys. Concomitant use with specific products can interfere with this clearance:

• Urine Alkalinizing Agents: Drugs that raise urine pH, such as carbonic anhydrase inhibitors or sodium bicarbonate, can reduce the clearance of amantadine, leading to increased plasma concentrations. This may necessitate a dosage review.
• Specific Antimalarials and Diuretics: Quinidine and the combination product triamterene/hydrochlorothiazide have been reported to reduce the renal excretion of amantadine, potentially resulting in elevated plasma levels and increased risk of side effects.

Increased CNS and Anticholinergic Effects

Combining amantadine with other agents that affect the central nervous system or possess anticholinergic properties can lead to additive side effects:

• Anticholinergic Agents and Neuroleptics: Co-administration with anticholinergic agents may increase the risk of side effects such as hallucinations, confusion, and nightmares. If abrupt discontinuation of amantadine is required in patients concurrently taking neuroleptic agents, close monitoring is advised due to isolated reports of worsening or occurrence of symptoms resembling Neuroleptic Malignant Syndrome (NMS).
• Other CNS-Active Drugs: General caution is advised when using Symetrel with any drug that has known CNS effects, with monitoring necessary for potential increased seizure frequency and for behavioral symptoms related to impulse control disorders when used with other dopamine agonists.

Symetrel (amantadine) modulates neurotransmission primarily within the central nervous system. It functions as a weak, non-competitive antagonist at the N-methyl-D-aspartate (NMDA) subtype of glutamate receptor. This interaction reduces the intracellular calcium influx and subsequent neuronal depolarization mediated by this ionotropic receptor.

Simultaneously, the drug acts on the dopaminergic system. It induces the release of dopamine from presynaptic storage vesicles in dopaminergic neurons and inhibits the reuptake of dopamine back into the presynaptic terminal. This dual action elevates the extracellular concentration of dopamine within the synaptic cleft, increasing the agonism at postsynaptic dopamine receptors.

Furthermore, amantadine binds to the sigma-1 (sigma1) receptor and functions as an agonist. Activation of the sigma1 receptor is thought to contribute to its dopaminergic effects by modulating the activity of tyrosine hydroxylase and potentially influencing dopamine release. The systemic consequence of these molecular interactions is a combined modulation of both glutamatergic and dopaminergic signaling pathways in the striatum and other brain regions.

Official Administration Guidelines

Symetrel, containing Amantadine Hydrochloride, is administered exclusively via the oral route in its various formulations, including immediate-release (IR) tablets, capsules, and syrup, and specific extended-release (ER) products. The method and frequency of use are governed by official instructions.

---

Dosage Regimens and Frequency

Indication	Starting Dose (IR)	Maintenance Dose (IR)	Dosing Frequency
Parkinsonism/EPS	100 mg once daily	100 mg twice daily (max 400 mg/ day)	Twice daily (divided doses)
Influenza A	200 mg daily	200 mg daily	Once or twice daily (e.g., 100 mg twice daily)

Immediate-release therapy for movement disorders typically begins with a 100 mg once-daily dose, which is often increased to the 100 mg twice-daily maintenance dose after one week. Extended-release products have specific once-daily timing, such as in the morning or at bedtime, and are not interchangeable with other formulations.

Procedural Use and Special Populations

For proper administration, solid dosage forms, particularly extended-release tablets and capsules, must be swallowed whole and must not be crushed, chewed, or divided, as this could alter the intended release of the medication. The medicine can generally be taken with or without food.

Official instructions require dose adjustments for certain patient groups. For older adults (aged 65 and over), the dose is commonly reduced to 100 mg once daily. Dose modification is also mandatory for patients with impaired kidney function, and the dosing interval must be lengthened based on their Creatinine Clearance. If long-term treatment is to be discontinued, the dosage must be gradually reduced (tapered) rather than stopped abruptly.

Research Evidence / Overview of Studies for Symetrel

The clinical evaluation of Symetrel involves research across two distinct therapeutic domains: movement disorders and viral illness. This overview summarizes the structure of the evidence, the types of studies conducted, and what aspects of the medicine remain uncertain, without providing any clinical advice or guidance.

---

Evidence for use in Parkinsonian Motor Symptoms

Symetrel was studied for its use in conditions involving difficulty with movement, including idiopathic Parkinson's disease. Research utilized controlled study designs, including randomized clinical trials, which examined core motor symptoms, such as rigidity, tremor, and slowness, assessed by standardized rating scales.

Research describes how symptoms evolved in the observed populations. Some studies described patterns in measured motor scores. What remains uncertain is the full characterization of the long-term patterns; historical data exists, but follow-up durations were limited in many modern trials.

---

Evidence for use in Levodopa-Induced Dyskinesia

The research base for this indication is defined by Randomized Controlled Trials (RCTs) and Phase 3 clinical trials. These studies examined adults with advanced Parkinson's disease experiencing involuntary movements, or dyskinesia. Research monitored outcomes reflecting daily functioning, specifically the severity of dyskinesia and changes in the duration of functional "ON" time.

Studies reported consistent measurements of dyskinesia severity over defined time intervals. Open-label follow-up research explored patterns observed over continuous use, with some data spanning up to two years, and reported measured changes in the observed population.

---

What is Still Uncertain About Symetrel

Major evidence gaps include the inconsistency of findings for MS-related fatigue, where the certainty remains low. The utility of historical evidence for Influenza A is also a major gap; the original studies monitored acute illness, but the continued high rate of viral resistance means the research provides limited insight into its use against contemporary circulating viral strains. Overall, evidence quality varies across studies, and research provides context about group patterns, but findings describe group patterns, not personal outcomes.

Key Studies & References

1. An updated meta-analysis of amantadine for treating dyskinesia in Parkinson's disease
2. Comparing Medicines to Help Patients with Multiple Sclerosis Feel Less Fatigued—The TRIUMPHANT-MS Study
3. Amantadine - StatPearls (NCBI Bookshelf)

Common questions about Symetrel (FAQ)

---

Q: What is Symetrel (Amantadine)?

A: Symetrel is a prescription medication primarily approved by the FDA for treating certain symptoms of Parkinson's disease and for the prevention and treatment of certain types of influenza A. It is also sometimes used off-label for other conditions, based on clinical judgment.

---

Q: How does Symetrel work?

A: Amantadine's exact mechanism in Parkinson's disease is not fully understood but may involve affecting dopamine and NMDA receptors in the brain. For influenza, it is thought to interfere with the uncoating of the virus.

---

Q: Who should not take Symetrel?

A: Symetrel is generally not recommended for individuals with a history of severe kidney disease or those who have shown a known hypersensitivity to the drug. A healthcare provider is the best source for determining individual appropriateness.

---

Q: What are the common side effects observed in studies?

A: Common side effects reported in clinical trials include nausea, dizziness, insomnia, and dry mouth. Not everyone experiences these effects, and they are usually mild. Livedo reticularis (a skin discoloration) has also been reported, particularly with longer-term use.

---

Q: Is Symetrel suitable for all types of flu?

A: Symetrel is approved only for the prevention and treatment of respiratory illness caused by Influenza A virus strains. It is not effective against Influenza B or other viral infections. The Centers for Disease Control and Prevention (CDC) provides current guidance on its use against circulating strains.

How to Store and Dispose of Amantadine Hydrochloride (Symetrel)

Symetrel, containing Amantadine Hydrochloride, must be stored under specific environmental controls as mandated by regulatory labeling to maintain stability.

Storage Conditions

Requirement	Specifics
Temperature	Store at controlled room temperature, defined as 20 C to 25 C (68 F to 77 F).
Protection	Keep the container tightly closed and away from excess heat and moisture.
Container Rule	Store the medicine in the original container in which it was dispensed.
Child Safety	Must be kept out of the reach of children, requiring immediate locking of safety caps.

Disposal

Unused or expired Amantadine Hydrochloride should be disposed of through a drug take-back program when available. If a program is inaccessible, the medication may be prepared for household trash by mixing it with an undesirable substance, sealing it in a container, and discarding it.